Cardiovascular changes in patients with non-severe Plasmodium vivax malaria

Aristoteles Comte Alencar-Filho, Amazonas Federal University
Joao Marcos Bemfica Barbosa Ferreira, Amazonas State University
Jorge Salinas, Emory University
Camila Fabbri, North University Center
Wuelton Marcelo Monteiro, Amazonas State University
Andre Machado Siqueira, Fundacao Oswaldo Cruz
Katashi Okoshi, Botucatu Medical School
Marcus Vinicius Guimaraes Lacerda, Amazonas State University
Marina Politi Okoshi, Botucatu Medical School

Journal Title: International Journal of Cardiology: Heart and Vasculature
Volume: Volume 11
Publisher: Elsevier | 2016-06-01, Pages 12-16
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.ijcha.2016.03.004
Permanent URL: https://pid.emory.edu/ark:/25593/s38s0

Final published version: http://dx.doi.org/10.1016/j.ijcha.2016.03.004

Copyright information:
Copyright © 2016 The Authors
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed December 3, 2018 3:47 AM EST
Cardiovascular changes in patients with non-severe
Plasmodium vivax malaria☆

Aristoteles Comte Alencar-Filho a,⁎, Joao Marcos Bemifica Barbosa Ferreira b, Jorge Luis Salinas c, Camila Fabbri d, Wuelton Marcelo Monteiro b,e, Andre Machado Siqueira f, Katashi Okoshi g, Marcus Vinicius Guimaraes Lacerda b,h, Marina Politi Okoshi g

a Amazonas Federal University, Manaus, Brazil
b Amazonas State University (UEA), Manaus, Brazil
c Emory University, Atlanta, United States
d North University Center, Pharmacy School, Manaus, Brazil
e Tropical Disease Center “Dr. Heitor Vieira Dourado”, Manaus, Brazil
g National Institute of Infectology Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
h Botucatu Medical School, UNESP, Botucatu, Brazil

Abstract

Article history:
Received 4 January 2016
Accepted 4 March 2016
Available online 10 March 2016

Background: Cardiovascular system involvement in patients with Plasmodium vivax malaria has been poorly addressed. The aim of this study was to evaluate cardiac structures and function, and serum markers of cardiovascular injury in patients with the non-severe form of vivax malaria in Manaus, Amazonas State, Brazil.

Methods and results: We prospectively evaluated 26 patients with vivax malaria in an outpatient referral hospital and compared results with a control group of 25 gender- and age-matched healthy individuals. Patients underwent clinical evaluation, laboratory tests, and transthoracic echocardiography at first evaluation (day zero, D0) and seven days (D7) after malaria diagnosis. At D0 echocardiography showed higher left ventricular (LV) systolic diameter (28.8 ± 2.82 vs 30.9 ± 4.03 mm; p = 0.037) and LV diastolic volume (82.4 ± 12.3 vs 93.8 ± 25.9 ml; p = 0.05), and lower LV ejection fraction (Teicholz method: 73.2 ± 6.59 vs 68.4 ± 4.87%; p = 0.004) in patients compared to controls. Right ventricle (RV) fractional area change (54.7 ± 5.11 vs 50.5 ± 6.71%; p = 0.014) was lower, and RV myocardial performance index (0.21 ± 0.07 vs 0.33 ± 0.19; p = 0.007), and pulmonary vascular resistance (1.13 ± 0.25 vs 1.32 ± 0.26 Woods unit; p = 0.012) were higher in patients than controls. Patients presented higher serum levels of unconjugated bilirubin (0.24 ± 0.15 vs 1.30 ± 0.89 mg/dL; p < 0.001), soluble vascular cell adhesion molecule – 1 (sVCAM-1; 453 ± 143 vs 1983 ± 880 ng/mL; p < 0.001), N-terminal prohormone brain natriuretic peptide (0.59 ± 0.86 vs 1.08 ± 0.81 pg/mL; p = 0.045), and troponin T (861 ± 338 vs 1037 ± 264 pg/mL; p = 0.045), and lower levels of plasma nitrite (13.42 ± 8.15 vs 8.98 ± 3.97 μM; p = 0.016) than controls. Most alterations had reversed by D7.

Conclusion: Patients with non-severe Plasmodium vivax malaria present subclinical reversible cardiovascular changes.

© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Malaria, a common parasitic disease affecting humans, is one of the most important public health issues in developing countries [1]. In 2013, there were 104 countries with endemic malaria, with approximately 198 million people affected and an estimated 584 thousand deaths [1].

Malaria pathophysiology has been extensively studied. However, since the first reports by Laveran [2] in 1884 describing myocardial and coronary changes in patients dying from malaria, few studies have carefully evaluated the cardiovascular system in malaria. These clinical and experimental studies have suggested that acute infection is accompanied by parasite sequestration and obstruction in microvascular coronary and myocardial injury caused by parasite released proteins as well as inflammatory cytokines and anemia [3–8]. More recently, falciparum malaria patients were shown to present endothelial
dysfunction with impaired vascular nitric oxide bioavailability and increased pulmonary artery pressure [4,9]. All studies on cardiovascular involvement in malaria have been performed on Plasmodium falciparum malaria, which is related to the most severe form of the disease affecting several organs and systems [10]. Of the various Plasmodium species, Plasmodium vivax was previously considered to cause a benign non-fatal infection. However, in the last decade several reports have linked P. vivax to systemic complications involving the central nervous system, renal and respiratory failure, abnormal bleeding, anemia, and jaundice [11–16]. To the best of our knowledge, there are no studies analyzing the cardiovascular system during P. vivax malaria. In this study, we evaluated cardiac structures and function by Doppler-echocardiogram and plasmatic markers of cardiovascular injury in patients with the non-severe form of P. vivax malaria in Manaus, Amazonas State, Brazil.

2. Materials and methods

2.1. Study subjects

In a case–control study, we prospectively evaluated outpatients with P. vivax malaria attending the Dr. Heitor Vieira Dourado Tropical Medicine Foundation (FMT-HVD), in Manaus, Brazil, between December 2012 and March 2013. The FMT-HVD is a tertiary care center for infectious diseases, where patients can either seek attention directly or be referred for specialized care in neighboring municipalities. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by FMT-HVD Research Ethics Committee. All individuals signed the informed consent.

Patients aged 18–60 years were eligible to participate if they had no known illness and were diagnosed with P. vivax malaria to be treated out of hospital (P. vivax group, n = 26). Age and gender-matched individuals testing negative for malaria comprised the Control group (n = 25). The controls had similar economic conditions and lived in the same neighborhood as the patients. Exclusion criteria included electrocardiographic changes suggesting regional abnormalities, heart valve disease, and previously diagnosed severe diseases such as stage C heart failure, renal or liver insufficiency, cancer, pregnancy, malaria other than P. vivax, or severe malaria needing in-hospital treatment according to the World Health Organization [1]. All patients had positive thick blood smear and real-time qPCR assay for P. vivax malaria. Controls tested negative in both tests. Patients were treated with a combination of chloroquine and primaquine or a combination of artesunate and amodiaquine.

All individuals were subjected to the following: medical history evaluation, physical examination, 12-lead resting electrocardiogram, thoracic Doppler-echocardiogram, and Laboratory investigation. In patients, clinical and laboratory evaluation was performed before treatment (day zero, D0) and seven days after starting treatment (day seven, D7). Medical history and physical examination were performed to assess general health and to clinically exclude diseases or conditions described in the exclusion criteria. Blood pressure was measured by the auscultatory technique with a conventional mercury sphygmomanometer.

2.2. Echocardiographic evaluation

A standard echocardiography system (General Electric Medical Systems, Vivid 3) was used to measure cardiac structures as previously described and following American Society of Echocardiography recommendations [17–20]. All echocardiograms were performed by the same examiner (JMBBF). With individuals positioned in left lateral decubitus position and monitored with an electrocardiographic lead, the following echocardiographic cuts were performed: short parasternal axis to measure ventricles, aorta and left atrium; apical 2, 4 and 5 chambers to evaluate ventricular cavities and systolic and diastolic function. The average of three measurements was calculated for each variable. The following left ventricular (LV) structures were measured by two-dimensional guided M-mode images: diastolic and systolic diameters (LVDD and LVSD, respectively), and diastolic and systolic volume (LVDV and LVSV, respectively). LV systolic function was evaluated by measuring ejection fraction according to the Teicholz index, endocardial fractional shortening, and myocardial performance index (Tei index) [21]. Right ventricle (RV) was structurally evaluated by measuring diastolic and systolic areas. RV systolic function was evaluated by fractional area change (FAC), and Tei index. Pulmonary vascular resistance (PVR) was estimated by Doppler echocardiography [22] according to the formula: PVR = tricuspid regurgitation peak velocity/right ventricular outflow tract velocity time integral) X 10 + 0.16. Pulmonary artery systolic pressure (PASP) was estimated by Doppler echocardiography using the modified Bernoulli equation 22: PASP = 4 X (tricuspid regurgitation peak velocity) [2] + right atrial pressure. Right atrial pressure was estimated from inferior vena cava diameter [22].

2.3. Laboratorial analysis

Venous blood samples were obtained after a 12–15 h overnight fast in EDTA-coated tubes. Plasma was frozen at — 80 °C in tubes containing 5 µL antioxidant butyl hydroxytoluene (BHT, 20 µM), proteases inhibitor (aprotinin, 2 mg/mL), phenylmethylsulphonyl fluoride (PMSF, 1 mM), and benzamidine (2 mM). Nitrite plasma concentration was quantified by colorimetry using a commercially available nitric oxide assay kit (Cayman, Chemical Company, AnnArbor, Michigan, USA). Concentrations of N-terminal prohormone brain natriuretic peptide (NT-proBNP) and troponin T were measured by ELISA using commercially available kits (USCN Life Science Inc., Houston, Texas, USA). Soluble vascular cell adhesion molecule (sVCAM)-1 concentration was analyzed by immunoassay using a commercially kit (R&D Systems, Inc., Minneapolis, Minnesota, USA). All kits used in this study are available for laboratory research use only, not for human diagnostics.

Subjects were tested for malaria by thick blood smear. Parasite density was calculated by the arithmetic mean of two concordant readings; the white blood cell count was obtained from total blood count analysis as previously described [23]. In case of discordance (species-specific, or in the density quantification whenever a discrepancy was higher than 10%), a third reading was performed by a senior investigator (WMM). Real-time qPCR was performed as previously described [24] to confirm P. vivax malaria.

2.4. Statistical analysis

Variables are presented as mean and standard deviation or median and minimum and maximum values. Comparisons between periods were performed by Student’s t test for dependent data and comparisons between groups were performed by unpaired Student’s t test. Categorical parameters were compared by Fisher’s exact test. The association between variables was assessed with Pearson’s correlation coefficient. The level of significance was 5%. Statistical analyses were performed using IBM SPSS Statistics software Version 21.

3. Results

Baseline characteristics for controls and patients at day zero (D0) are presented in Table 1. Heart rate, although within the normal range, was higher in P. vivax group than Controls.

The P. vivax group had a mean peripheral parasitemia of 2844 ± 3286 parasites/mm3, ranging from 87 to 11,806 parasites/mm3. Laboratory data are shown in Table 2. P. vivax D0 had increased plasma concentrations of unconjugated bilirubin, troponin T, NT-proBNP, and sVCAM-1 and decreased platelet count and nitrite levels compared to Controls. At D7, unconjugated bilirubin, troponin T, NT-proBNP, and sVCAM-1 were lower, and platelet count and nitrite levels higher than D0.
five percent of malaria patients had less than 150,000 platelets/μL at D0; no patient presented clinical bleeding or severe thrombocytopenia (<50,000 platelets/μL).

LV echocardiographic data are shown in Table 3. At D0, the P. vivax group presented higher LV systolic diameter and lower ejection fraction and endocardial fractional shortening than Controls. LV variables did not significantly differ between D7 and D0 in the P. vivax group. RV data are shown in Table 4. At D0, the P. vivax group had higher RV diastolic and systolic area, Tei index, and pulmonary vascular resistance, and lower fractional area change than Controls. In P. vivax patients, fractional area change was higher and pulmonary vascular resistance lower in D7 than D0. At D0, NT-proBNP levels positively correlated with RV diastolic (r = 0.409; P = 0.038) and systolic (r = 0.435; P = 0.026) areas were reversible after treatment, as suggested by the higher fractional area change and the lower pulmonary vascular resistance at D7 compared to D0. LV systolic diameter; LVDV: LV diastolic volume; EF: ejection fraction; EFS: LV endocardial fractional shortening. Unpaired Student’s t test or Fisher’s exact test (*).

4. Discussion

In this study we evaluated cardiac structures and function by Doppler echocardiography and systemic markers of cardiovascular injury in patients with the non-severe form of P. vivax malaria at the beginning of infection and seven days later.

Malaria was diagnosed by examining thick blood smears and P. vivax malaria was confirmed by real-time qPCR assay. As jaundice is a diagnostic criteria for severe malaria, no icteric patient was included in this study. Nonetheless, mean unconjugated bilirubin values were higher at D0 in P. vivax than Controls suggesting a low degree of hemolysis. Malaria patients had a slight decrease in platelet count at D0, which is common observed in vivax malaria and may be related to platelet phagocytosis [25,26]. Platelet counting often normalizes after treatment [25].

As markers of myocardial injury, we evaluated plasma concentrations of troponin T and NT-proBNP, which were higher at D0 in P. vivax than Controls and D7 P. vivax. The troponin T levels in our malaria patients suggest a slight degree of myocardial injury. NT-proBNP concentration is often used for heart failure diagnosis and prognosis. More recently, it has also been considered a good biomarker for pulmonary arterial hypertension and right ventricular dysfunction [27].

The higher NT-proBNP levels in D0 P. vivax than Controls is probably related to acute dilation of the left and right ventricles.

Soluble vascular cell adhesion molecule-1 contributes to endothelial activation and dysfunction, which are involved in the pathogenesis of several infectious diseases [28]. In hemolytic conditions such as sickle-cell anemia and malaria, sVCAM-1 levels are usually increased [28]. It facilitates adhesion of infected and non-infected blood red cells to endothelium, resulting in fibrin and platelet deposition, and microvascular sequestration and obstruction [29–31]. Expression of sVCAM-1 may be induced by proinflammatory cytokines and nitric oxide depletion [4, 32]. Nitric oxide depletion also impairs vasodilation [33]. In this study, plasma concentration of sVCAM-1 was higher and nitrite levels lower in D0 P. vivax than Controls. Similar results were found in children with falciparum malaria [4] and endothelial activation was previously observed in uncomplicated vivax malaria [34]. Nitrite is considered as a physiological storage pool of nitric oxide that can be reduced to bioactive nitric oxide in hypoxic conditions to mediate physiological responses in blood and tissue [35]. D7 sVCAM-1 was lower and nitrite higher than at D0 in malaria patients.

In this study, the P. vivax group presented slight left ventricular dilation with reduced systolic function compared to Controls at D0. Left ventricular echocardiographic parameters did not significantly differ between D7 and D0 in the P. vivax group. At D0, P. vivax group presented right ventricular dilation, characterized by increased diastolic and systolic areas, and right ventricular dysfunction, characterized by reduced fractional area change and increased Tei index, with increased pulmonary vascular resistance. Fractional area change has been used to evaluate right ventricular systolic function, presenting a good correlation with ejection fraction estimated by cardiac magnetic resonance imaging [36]. Furthermore, in this study, right ventricular diastolic and systolic area and Tei index positively correlated with NT-proBNP levels. Alterations in right ventricle function and pulmonary vascular resistance were reversible after treatment, as suggested by the higher fractional area change and the lower pulmonary vascular resistance at D7 compared to D0. Right ventricular dilation may be the first indicator of an acute increase in pulmonary vascular resistance; and increased pulmonary vascular resistance can be related to vasoconstriction, inflammation, and obstruction of pulmonary arteries in malaria [22,37].

Table 2

Baseline characteristics at day zero (D0).

| Control (n = 25) | P. vivax (n = 26) | P-value*
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>44.5 ± 8.43</td>
<td>41.7 ± 13.7</td>
</tr>
<tr>
<td>Female, %</td>
<td>44.0</td>
<td>30.8</td>
</tr>
<tr>
<td>Height, m</td>
<td>1.67 ± 0.07</td>
<td>1.67 ± 0.08</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>79.3 ± 15.0</td>
<td>79.0 ± 13.9</td>
</tr>
<tr>
<td>BMI</td>
<td>28.3 ± 4.5</td>
<td>28.2 ± 5.07</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>121 ± 11.6</td>
<td>121 ± 12.2</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>79 ± 8.6</td>
<td>78 ± 8.1</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>66 ± 7.6</td>
<td>76 ± 13.2</td>
</tr>
</tbody>
</table>

Data are mean and standard deviation. D0: day zero; D7: day seven; UCB: unconjugated bilirubin; NT-proBNP: N-terminal prohormone brain natriuretic peptide; sVCAM-1: soluble vascular cell adhesion molecule; unpaired Student’s t test or Fisher’s exact test (*).

Table 3

Left ventricular echocardiographic data.

| Control (n = 25) | P. vivax D0 (n = 26) | P. vivax D7 (n = 26) | P-Value
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LVSD, mm</td>
<td>28.8 ± 2.82</td>
<td>30.9 ± 4.03</td>
<td>0.037</td>
</tr>
<tr>
<td>LVDV, mL</td>
<td>82.4 ± 12.3</td>
<td>93.8 ± 25.9</td>
<td>0.150</td>
</tr>
<tr>
<td>EF, %</td>
<td>73.2 ± 6.59</td>
<td>68.4 ± 4.87</td>
<td>0.004</td>
</tr>
<tr>
<td>EFS, %</td>
<td>42.8 ± 5.81</td>
<td>38.4 ± 3.28</td>
<td>0.003</td>
</tr>
<tr>
<td>Tei index</td>
<td>0.31 ± 0.04</td>
<td>0.36 ± 0.12</td>
<td>0.35 ± 0.10</td>
</tr>
</tbody>
</table>

Data are mean and standard deviation. D0: day zero; D7: day seven; LVSD: left ventricular systolic diameter; LVDV: LV diastolic volume; EF: ejection fraction; EFS: LV endocardial fractional shortening. Unpaired Student’s t test P. vivax D0 vs Control; and paired Student’s t test P. vivax D7 vs P. vivax D0.
Table 4
Right ventricular echocardiographic data.

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 25)</th>
<th>P. vivax D0 (n = 26)</th>
<th>P. vivax D7 (n = 26)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DA, cm²</td>
<td>13.0 ± 3.19</td>
<td>15.3 ± 2.96</td>
<td>15.1 ± 2.55</td>
<td>0.009</td>
</tr>
<tr>
<td>SA, cm²</td>
<td>6.41 ± 1.27</td>
<td>7.45 ± 1.46</td>
<td>6.90 ± 1.41</td>
<td>0.009</td>
</tr>
<tr>
<td>FAC, %</td>
<td>54.7 ± 5.11</td>
<td>50.5 ± 6.71</td>
<td>55.7 ± 6.90</td>
<td>0.014</td>
</tr>
<tr>
<td>Tei index</td>
<td>0.21 ± 0.07</td>
<td>0.33 ± 0.19</td>
<td>0.27 ± 0.10</td>
<td>0.007</td>
</tr>
<tr>
<td>PVR, Wood units</td>
<td>1.13 ± 0.25</td>
<td>1.32 ± 0.26</td>
<td>1.17 ± 0.19</td>
<td>0.012</td>
</tr>
<tr>
<td>PASP, mm Hg</td>
<td>19.2 ± 2.95</td>
<td>19.7 ± 3.05</td>
<td>19.8 ± 4.19</td>
<td>0.576</td>
</tr>
</tbody>
</table>

Data are mean and standard deviation. D0: day zero; D7: day seven; DA: diastolic area; SA: systolic area; FAC: fractional area change; PVR: pulmonary vascular resistance; PASP: pulmonary artery systolic pressure. Unpaired Student’s t test P. vivax D0 vs Control; and paired Student’s t test P. vivax D7 vs P. vivax D0.

We have not identified any other studies in literature evaluating cardiac structures and function in patients with vivax malaria. Our data suggest that outpatients with P. vivax malaria present subclinical cardiovascular changes and allow us to hypothesize that events previously described in severe falciparum malaria [4,9,38,39] also occur in non-severe vivax malaria. Products from low grade hemolysis of parasitized red blood cells induce a reduction in plasma nitrite, which is related with nitric oxide bioavailability. Increased expression of cell adhesion molecules such as sVCAM-1 facilitates adherence to vascular endothelium and destruction of infected reticulocytes and non-infected erythrocytes. Nitric oxide depletion decreases vasodilation therefore increasing pulmonary vascular resistance and impairing right ventricular function. Additionally, left ventricular dilation and dysfunction may result from infection, depleted nitric oxide-induced increase in afterload, and/or microvascular obstruction. The increase in NT-proBNP, suggesting dilation of cardiac chambers, and troponin T, suggesting myocyte injury, re-inforces myocardial injury during P. vivax malaria. Most alterations are reversible seven days after treatment.

5. Limitations

This study evaluated a small sized sample of outpatients with vivax malaria, which allowed us to raise a hypothesis on the pathophysiologic events involved in cardiovascular changes. Therefore, additional studies are needed to evaluate a larger sample of both P. vivax malaria in- and out-patients in order to confirm our results and to extend the understanding of vivax malaria patients to the severe form of the disease.

In conclusion, patients with non-severe P. vivax malaria present subclinical cardiovascular changes.

Conflicts of interest

The authors report no conflicts of interest.

Acknowledgements

We are grateful to Colin Edward Knaggs for English editing. Financial support was provided by CNPq (306857/2012-0, 306845/2012-1, and 479085/2013-7).

References


